CRISPR Therapeutics AG (NASDAQ:CRSP) Expected to Post Earnings of -$1.91 Per Share

Analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) will post earnings of ($1.91) per share for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($2.18) to ($1.65). CRISPR Therapeutics posted earnings per share of ($1.51) during the same quarter last year, which would indicate a negative year over year growth rate of 26.5%. The business is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full-year earnings of ($7.69) per share for the current year, with EPS estimates ranging from ($9.76) to ($3.03). For the next fiscal year, analysts forecast that the firm will report earnings of ($7.21) per share, with EPS estimates ranging from ($11.45) to ($3.21). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last released its earnings results on Monday, February 14th. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.10). CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The business had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $5.39 million.

Several brokerages have recently commented on CRSP. Truist Financial restated a “buy” rating and set a $220.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, February 16th. Credit Suisse Group started coverage on CRISPR Therapeutics in a research note on Thursday. They set a “neutral” rating and a $78.00 price target on the stock. StockNews.com started coverage on CRISPR Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Stifel Nicolaus cut their target price on CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. Finally, Barclays lowered their price target on CRISPR Therapeutics from $148.00 to $107.00 in a report on Wednesday, February 16th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $125.43.

Several institutional investors have recently added to or reduced their stakes in CRSP. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth about $289,982,000. Nikko Asset Management Americas Inc. lifted its holdings in CRISPR Therapeutics by 31.3% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 4,319,471 shares of the company’s stock valued at $330,526,000 after acquiring an additional 1,029,955 shares during the period. Norges Bank acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $44,918,000. Renaissance Technologies LLC acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $43,865,000. Finally, Capital World Investors acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $31,940,000. 55.21% of the stock is owned by hedge funds and other institutional investors.

Shares of CRISPR Therapeutics stock opened at $49.62 on Friday. The firm has a market cap of $3.84 billion, a P/E ratio of 11.23 and a beta of 2.02. CRISPR Therapeutics has a 12 month low of $48.38 and a 12 month high of $169.76. The stock’s fifty day moving average price is $60.78 and its 200-day moving average price is $71.40.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Stories

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.